Regeneron Pharmaceuticals has announced a new manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies to enhance its production capacity for biologic medicines at Fujifilm's facility ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies to manufacture ...
New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs in the ...
Hosted on MSN
Regeneron targets $7B in U.S. manufacturing investment as R&D and commercial launches accelerate
CEO Leonard Schleifer reported "double-digit net sales growth for 3 of our leading products," highlighting a 26% increase in Dupixent, 24% for Libtayo at constant exchange rates, and a 10% increase ...
HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, ...
Contract manufacturer FujiFilm Diosynth Biotechnologies, which has been expanding its footprint in Holly Springs, has signed a $3 billion agreement to make treatments for Regeneron Pharmaceuticals.
Switzerland-based Roche said it will spend $50B in the U.S. over the next five years and create 12,000 jobs. The investment will fund research and development facilities as well as new manufacturing ...
Regeneron Pharmaceuticals plans to set up a global capability centre in Hyderabad, with operations starting in 2026 and ...
President Donald Trump on Thursday announced a deal with drugmaker Regeneron to lower the cost of its pharmaceutical products as part of the White House’s signature drug pricing initiative. The deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results